Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1594865 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1595205 | 0.91 | AAK1 (0.44) | KDM4ENPC1RAB9AHPGDMEN1 | |
| SCHEMBL1595844 | 0.91 | AAK1 (0.44) | KDM4ENPC1RAB9AHPGDMEN1 | |
| SCHEMBL1595384 | 0.89 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1595174 | 0.89 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL177973 | 0.89 | KDM4E (0.47) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL177970 | 0.89 | KDM4E (0.47) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1595483 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1594821 | 0.85 | KDM4E (0.51) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1594616 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | claimed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | claimed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | claimed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | claimed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | claimed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | claimed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| CN-102395562-A | Novel P2X7R antagonists and uses thereof | AFFECTIS PHARMACEUTICALS AG | 2012-03-28 | — | — | CN | disclosed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | disclosed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | KDM4E 3713/4885ALDH1A1 1830/4885NPC1 1162/4885 |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | KDM4E 3713/4885ALDH1A1 1830/4885NPC1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.